Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase

May Khanna, Bhadrani Chelladurai, Aruna Gavini, Liwei Li, Minghai Shao, David Courtney, John J. Turchi, Daniela Matei, Samy Meroueh

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Tissue transglutaminase (TG2) is a transpeptidase involved in protein cross-linking through generation of e-(γ-glutamyl)lysine isopeptide bonds. It also promotes cell adhesion through interaction with fibronectin and facilitates formation of fibronectin-integrin complexes. This interaction is involved in tumor cell adhesion to the matrix and in the process of tumor dissemination. Its inhibition by small molecules may therefore be useful in blocking metastasis. To that end, we screened more than 800,000 compounds following an in silico docking approach targeting two distinct cavities in the vicinity of the fibronectin-binding site on TG2. A total of 120 compounds were acquired and tested in cell culture-based assays for inhibition of ovarian tumor cell adhesion and proliferation. Seven compounds showed more than 50% inhibition of cell adhesion at a concentration of 25 μmol/L. A follow-up fluorescence polarization study revealed that one compound in particular (ITP-79) inhibited binding of a TG2 peptide to a 42-kDa fragment of fibronectin in a dose-dependent manner. This inhibition was confirmed in cancer cells by coimmunoprecipitation. A competition assay with surface plasmon resonance showed that ITP-79 modulated binding of TG2 to fibronectin. Direct binding of compounds that inhibited adhesion to TG2 were examined with differential scanning fluorimetry, which measures the effect of the compound on the melting temperature of the target. Two compounds, including ITP-79, reduced TG2 stabilization, mimicking the effects of GTP, a known negative allosteric regulator of TG2 enzymatic function. This suggests a potential allosteric mechanism for the compound in light of its distal target site.

Original languageEnglish (US)
Pages (from-to)626-636
Number of pages11
JournalMolecular Cancer Therapeutics
Volume10
Issue number4
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Fibronectins
Cell Adhesion
Neoplasms
Cell-Matrix Junctions
Peptidyl Transferases
Fluorometry
Fluorescence Polarization
Surface Plasmon Resonance
Guanosine Triphosphate
Integrins
Computer Simulation
Freezing
Lysine
Cell Culture Techniques
Binding Sites
Cell Proliferation
transglutaminase 2
Neoplasm Metastasis
Peptides
Temperature

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Khanna, M., Chelladurai, B., Gavini, A., Li, L., Shao, M., Courtney, D., ... Meroueh, S. (2011). Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. Molecular Cancer Therapeutics, 10(4), 626-636. https://doi.org/10.1158/1535-7163.MCT-10-0912

Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. / Khanna, May; Chelladurai, Bhadrani; Gavini, Aruna; Li, Liwei; Shao, Minghai; Courtney, David; Turchi, John J.; Matei, Daniela; Meroueh, Samy.

In: Molecular Cancer Therapeutics, Vol. 10, No. 4, 04.2011, p. 626-636.

Research output: Contribution to journalArticle

Khanna, M, Chelladurai, B, Gavini, A, Li, L, Shao, M, Courtney, D, Turchi, JJ, Matei, D & Meroueh, S 2011, 'Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase', Molecular Cancer Therapeutics, vol. 10, no. 4, pp. 626-636. https://doi.org/10.1158/1535-7163.MCT-10-0912
Khanna, May ; Chelladurai, Bhadrani ; Gavini, Aruna ; Li, Liwei ; Shao, Minghai ; Courtney, David ; Turchi, John J. ; Matei, Daniela ; Meroueh, Samy. / Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. In: Molecular Cancer Therapeutics. 2011 ; Vol. 10, No. 4. pp. 626-636.
@article{3f9f54d3dcdf48f489a9aeb959a28c58,
title = "Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase",
abstract = "Tissue transglutaminase (TG2) is a transpeptidase involved in protein cross-linking through generation of e-(γ-glutamyl)lysine isopeptide bonds. It also promotes cell adhesion through interaction with fibronectin and facilitates formation of fibronectin-integrin complexes. This interaction is involved in tumor cell adhesion to the matrix and in the process of tumor dissemination. Its inhibition by small molecules may therefore be useful in blocking metastasis. To that end, we screened more than 800,000 compounds following an in silico docking approach targeting two distinct cavities in the vicinity of the fibronectin-binding site on TG2. A total of 120 compounds were acquired and tested in cell culture-based assays for inhibition of ovarian tumor cell adhesion and proliferation. Seven compounds showed more than 50{\%} inhibition of cell adhesion at a concentration of 25 μmol/L. A follow-up fluorescence polarization study revealed that one compound in particular (ITP-79) inhibited binding of a TG2 peptide to a 42-kDa fragment of fibronectin in a dose-dependent manner. This inhibition was confirmed in cancer cells by coimmunoprecipitation. A competition assay with surface plasmon resonance showed that ITP-79 modulated binding of TG2 to fibronectin. Direct binding of compounds that inhibited adhesion to TG2 were examined with differential scanning fluorimetry, which measures the effect of the compound on the melting temperature of the target. Two compounds, including ITP-79, reduced TG2 stabilization, mimicking the effects of GTP, a known negative allosteric regulator of TG2 enzymatic function. This suggests a potential allosteric mechanism for the compound in light of its distal target site.",
author = "May Khanna and Bhadrani Chelladurai and Aruna Gavini and Liwei Li and Minghai Shao and David Courtney and Turchi, {John J.} and Daniela Matei and Samy Meroueh",
year = "2011",
month = "4",
doi = "10.1158/1535-7163.MCT-10-0912",
language = "English (US)",
volume = "10",
pages = "626--636",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase

AU - Khanna, May

AU - Chelladurai, Bhadrani

AU - Gavini, Aruna

AU - Li, Liwei

AU - Shao, Minghai

AU - Courtney, David

AU - Turchi, John J.

AU - Matei, Daniela

AU - Meroueh, Samy

PY - 2011/4

Y1 - 2011/4

N2 - Tissue transglutaminase (TG2) is a transpeptidase involved in protein cross-linking through generation of e-(γ-glutamyl)lysine isopeptide bonds. It also promotes cell adhesion through interaction with fibronectin and facilitates formation of fibronectin-integrin complexes. This interaction is involved in tumor cell adhesion to the matrix and in the process of tumor dissemination. Its inhibition by small molecules may therefore be useful in blocking metastasis. To that end, we screened more than 800,000 compounds following an in silico docking approach targeting two distinct cavities in the vicinity of the fibronectin-binding site on TG2. A total of 120 compounds were acquired and tested in cell culture-based assays for inhibition of ovarian tumor cell adhesion and proliferation. Seven compounds showed more than 50% inhibition of cell adhesion at a concentration of 25 μmol/L. A follow-up fluorescence polarization study revealed that one compound in particular (ITP-79) inhibited binding of a TG2 peptide to a 42-kDa fragment of fibronectin in a dose-dependent manner. This inhibition was confirmed in cancer cells by coimmunoprecipitation. A competition assay with surface plasmon resonance showed that ITP-79 modulated binding of TG2 to fibronectin. Direct binding of compounds that inhibited adhesion to TG2 were examined with differential scanning fluorimetry, which measures the effect of the compound on the melting temperature of the target. Two compounds, including ITP-79, reduced TG2 stabilization, mimicking the effects of GTP, a known negative allosteric regulator of TG2 enzymatic function. This suggests a potential allosteric mechanism for the compound in light of its distal target site.

AB - Tissue transglutaminase (TG2) is a transpeptidase involved in protein cross-linking through generation of e-(γ-glutamyl)lysine isopeptide bonds. It also promotes cell adhesion through interaction with fibronectin and facilitates formation of fibronectin-integrin complexes. This interaction is involved in tumor cell adhesion to the matrix and in the process of tumor dissemination. Its inhibition by small molecules may therefore be useful in blocking metastasis. To that end, we screened more than 800,000 compounds following an in silico docking approach targeting two distinct cavities in the vicinity of the fibronectin-binding site on TG2. A total of 120 compounds were acquired and tested in cell culture-based assays for inhibition of ovarian tumor cell adhesion and proliferation. Seven compounds showed more than 50% inhibition of cell adhesion at a concentration of 25 μmol/L. A follow-up fluorescence polarization study revealed that one compound in particular (ITP-79) inhibited binding of a TG2 peptide to a 42-kDa fragment of fibronectin in a dose-dependent manner. This inhibition was confirmed in cancer cells by coimmunoprecipitation. A competition assay with surface plasmon resonance showed that ITP-79 modulated binding of TG2 to fibronectin. Direct binding of compounds that inhibited adhesion to TG2 were examined with differential scanning fluorimetry, which measures the effect of the compound on the melting temperature of the target. Two compounds, including ITP-79, reduced TG2 stabilization, mimicking the effects of GTP, a known negative allosteric regulator of TG2 enzymatic function. This suggests a potential allosteric mechanism for the compound in light of its distal target site.

UR - http://www.scopus.com/inward/record.url?scp=79955757951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955757951&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0912

DO - 10.1158/1535-7163.MCT-10-0912

M3 - Article

C2 - 21330459

AN - SCOPUS:79955757951

VL - 10

SP - 626

EP - 636

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -